Artículos de revistas sobre el tema "Mutation BRAFV600E"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Mutation BRAFV600E".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Lee, Min Hee, Seong Eun Lee, Dong Wook Kim, Min Jeong Ryu, Sung Jin Kim, Sung Joong Kim, Yong Kyoung Kim et al. "Mitochondrial Localization and Regulation of BRAFV600E in Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAFV600E". Journal of Clinical Endocrinology & Metabolism 96, n.º 1 (1 de enero de 2011): E19—E30. http://dx.doi.org/10.1210/jc.2010-1071.
Texto completoSahm, Felix, David Capper, Matthias Preusser, Jochen Meyer, Albrecht Stenzinger, Felix Lasitschka, Anna-Sophie Berghoff et al. "BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis". Blood 120, n.º 12 (20 de septiembre de 2012): e28-e34. http://dx.doi.org/10.1182/blood-2012-06-429597.
Texto completoChakraborty, Dhritiman, Sunil Shakya, Sanjana Ballal, Shipra Agarwal y Chandrasekhar Bal. "BRAFV600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation". Journal of Pediatric Endocrinology and Metabolism 33, n.º 11 (26 de noviembre de 2020): 1465–74. http://dx.doi.org/10.1515/jpem-2020-0174.
Texto completoDiamond, Eli L., Benjamin Durham, Ahmet Dogan, Mariko Yabe, Kseniya Petrova-Drus, Raajit K. Rampal, Raajit K. Rampal et al. "Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Neoplasms". Blood 142, Supplement 1 (28 de noviembre de 2023): 1812. http://dx.doi.org/10.1182/blood-2023-187508.
Texto completoSong, Eyun, Meihua Jin, Ahreum Jang, Min Ji Jeon, Dong Eun Song, Hye Jin Yoo, Won Bae Kim, Young Kee Shong y Won Gu Kim. "Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAFV600E-Mutant Advanced Papillary Thyroid Carcinoma". Cancers 13, n.º 22 (22 de noviembre de 2021): 5846. http://dx.doi.org/10.3390/cancers13225846.
Texto completoKaneko, Masanao, Mitsuko Nakashima, Kiichi Sugiura, Natsuki Ishida, Satoshi Tamura, Shinya Tani, Mihoko Yamade et al. "Both MLH1 deficiency and BRAFV600E mutation are a unique characteristic of colorectal medullary carcinoma: An observational study". Medicine 102, n.º 38 (22 de septiembre de 2023): e35022. http://dx.doi.org/10.1097/md.0000000000035022.
Texto completoAscierto, Paolo A., David Minor, Antoni Ribas, Celeste Lebbe, Anne O'Hagan, Niki Arya, Mary Guckert et al. "Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma". Journal of Clinical Oncology 31, n.º 26 (10 de septiembre de 2013): 3205–11. http://dx.doi.org/10.1200/jco.2013.49.8691.
Texto completoMorris, Van K., Kanwal Pratap Singh Raghav, Arvind Dasari, Michael J. Overman, Bryan K. Kee, Benny Johnson, Christine Megerdichian Parseghian et al. "Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer." Journal of Clinical Oncology 39, n.º 3_suppl (20 de enero de 2021): 119. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.119.
Texto completoSmyrk, Thomas C., David Tougeron, Stephen N. Thibodeau, Shalini Singh, Andrea Muranyi, Kandavel Shanmugam, Thomas M. Grogan, Steven R. Alberts, Qian Shi y Frank A. Sinicrope. "Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 3576. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3576.
Texto completoChoi, Yun-Suk, Seong-Woon Choi y Jin-Wook Yi. "Prospective Analysis of TERT Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution". Journal of Clinical Medicine 10, n.º 10 (18 de mayo de 2021): 2179. http://dx.doi.org/10.3390/jcm10102179.
Texto completoSong, Young Shin, Seong-Keun Yoo, Hwan Hee Kim, Gyeongseo Jung, Ah-Reum Oh, Ji-Young Cha, Su-jin Kim et al. "Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer". Endocrine-Related Cancer 26, n.º 6 (junio de 2019): 629–41. http://dx.doi.org/10.1530/erc-17-0562.
Texto completoWang, Liye, Qianyi Lu, Kuikui Jiang, Ruoxi Hong, Shusen Wang y Fei Xu. "BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review". Oncology Research and Treatment 45, n.º 1-2 (24 de noviembre de 2021): 54–61. http://dx.doi.org/10.1159/000520453.
Texto completoGąsior-Perczak, Danuta, Artur Kowalik, Agnieszka Walczyk, Monika Siołek, Krzysztof Gruszczyński, Iwona Pałyga, Estera Mikina et al. "Coexisting Germline CHEK2 and Somatic BRAFV600E Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course". Cancers 11, n.º 11 (7 de noviembre de 2019): 1744. http://dx.doi.org/10.3390/cancers11111744.
Texto completoNikiforovich, P. A., A. P. Polyakov, I. V. Sleptsov, N. S. Boyko, Yu A. Gronskaya, N. I. Timofeeva y R. A. Chernikov. "Targeted therapy of anaplastic thyroid cancer". Head and Neck Tumors (HNT) 12, n.º 4 (8 de marzo de 2023): 33–38. http://dx.doi.org/10.17650/2222-1468-2022-12-4-33-38.
Texto completoEmile, Jean-François, Eli L. Diamond, Zofia Hélias-Rodzewicz, Fleur Cohen-Aubart, Frédéric Charlotte, David M. Hyman, Eunhee Kim et al. "Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease". Blood 124, n.º 19 (6 de noviembre de 2014): 3016–19. http://dx.doi.org/10.1182/blood-2014-04-570937.
Texto completoJin, Lei, Liang Zhou, Jian-Biao Wang, Li Tao, Xiao-Xiao Lu, Na Yan, Qian-Ming Chen, Li-Ping Cao y Lei Xie. "Whether Detection of Gene Mutations Could Identify Low- or High-Risk Papillary Thyroid Microcarcinoma? Data from 393 Cases Using the Next-Generation Sequencing". International Journal of Endocrinology 2024 (16 de enero de 2024): 1–12. http://dx.doi.org/10.1155/2024/2470721.
Texto completoSui, Jane Sze Yin, Marc Ladanyi, Charles M. Rudin, Alexander E. Drilon, Gregory J. Riely, Mark G. Kris y Michael Offin. "Clinicopathologic and mutational landscape of BRAFV600E-mutant non–small cell lung carcinoma." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 9084. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9084.
Texto completoSui, Jane Sze Yin, Marc Ladanyi, Charles M. Rudin, Alexander E. Drilon, Gregory J. Riely, Mark G. Kris y Michael Offin. "Clinicopathologic and mutational landscape of BRAFV600E-mutant non–small cell lung carcinoma." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 9084. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9084.
Texto completoLiu, Shiyang, Bo Jiao, Shuyu Li, Lu Zhao, Weihong Zheng, Kun Wang, Jing Xu et al. "Oestrogen receptor alpha in papillary thyroid carcinoma: association with clinical features and BRAFV600E mutation". Japanese Journal of Clinical Oncology 51, n.º 7 (24 de abril de 2021): 1051–58. http://dx.doi.org/10.1093/jjco/hyab058.
Texto completoJouenne, Fanélie, Sylvie Chevret, Emmanuelle Bugnet, Emmanuelle Clappier, Gwenaël Lorillon, Véronique Meignin, Aurélie Sadoux et al. "Genetic landscape of adult Langerhans cell histiocytosis with lung involvement". European Respiratory Journal 55, n.º 2 (5 de diciembre de 2019): 1901190. http://dx.doi.org/10.1183/13993003.01190-2019.
Texto completoDong, Si-Yang, Jie Chen, Er-Jie Xia, Ri-Xu Lin, Hai-Yan Du, Ou-Chen Wang, Xiao-Hua Zhang y Ru-Tian Hao. "Clinical Analysis of BRAFV600E Mutation and Its Correlation With Sonographic Image Characteristics in Papillary Thyroid Carcinoma in Chinese Coastal Areas". American Surgeon 86, n.º 5 (mayo de 2020): 450–57. http://dx.doi.org/10.1177/0003134820919734.
Texto completoElisei, Rossella, Clara Ugolini, David Viola, Cristiana Lupi, Agnese Biagini, Riccardo Giannini, Cristina Romei, Paolo Miccoli, Aldo Pinchera y Fulvio Basolo. "BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study". Journal of Clinical Endocrinology & Metabolism 93, n.º 10 (1 de octubre de 2008): 3943–49. http://dx.doi.org/10.1210/jc.2008-0607.
Texto completoYamazaki, Kentaro, Takayuki Yoshino, Katsuya Tsuchihara, Eiji Shinozaki, Kei Muro, Tomohiro Nishina, Kensei Yamaguchi et al. "Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics)." Journal of Clinical Oncology 33, n.º 3_suppl (20 de enero de 2015): 573. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.573.
Texto completoSoria, Xavier, Felip Vilardell, Óscar Maiques, Carla Barceló, Pol Sisó, Inés de la Rosa, Ana Velasco et al. "BRAFV600E Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics". Cancers 13, n.º 20 (11 de octubre de 2021): 5073. http://dx.doi.org/10.3390/cancers13205073.
Texto completoAttia, Abdallah S., Mohammad Hussein, Peter P. Issa, Ahmad Elnahla, Ashraf Farhoud, Brandon M. Magazine, Mohanad R. Youssef et al. "Association of BRAFV600E Mutation with the Aggressive Behavior of Papillary Thyroid Microcarcinoma: A Meta-Analysis of 33 Studies". International Journal of Molecular Sciences 23, n.º 24 (9 de diciembre de 2022): 15626. http://dx.doi.org/10.3390/ijms232415626.
Texto completoHong, Xiaoquan, Juxiang Li, Shaoyin Duan y Youkuang You. "Retrospective study of BRAFV600E mutation and CT features of papillary thyroid carcinoma". PeerJ 12 (24 de enero de 2024): e16810. http://dx.doi.org/10.7717/peerj.16810.
Texto completoJING, Fan-jing, Jun LIANG, Zhi-yong LIANG, Chao MENG, Wen LONG, Xiao-yi LI y Yan-song LIN. "BRAFV600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma". Chinese Medical Journal 126, n.º 16 (30 de agosto de 2013): 3013–18. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20122032.
Texto completoLi, Fei, Guangqi Chen, Chunjun Sheng, Aaron M. Gusdon, Yueye Huang, Zhongwei Lv, Huixiong Xu, Mingzhao Xing y Shen Qu. "BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis". Endocrine-Related Cancer 22, n.º 2 (15 de enero de 2015): 159–68. http://dx.doi.org/10.1530/erc-14-0531.
Texto completoOtieno, Steve Biko, Syed Nasir, Alva Weir y Robert Johnson. "Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors". Case Reports in Hematology 2020 (11 de diciembre de 2020): 1–4. http://dx.doi.org/10.1155/2020/8821415.
Texto completoKim, Suk Kyeong, Tae Sook Hwang, Young Bum Yoo, Hye Seung Han, Dong-Lim Kim, Kee-Ho Song, So Duk Lim, Wan Seop Kim y Nam Sun Paik. "Surgical Results of Thyroid Nodules according to a Management Guideline Based on the BRAFV600E Mutation Status". Journal of Clinical Endocrinology & Metabolism 96, n.º 3 (1 de marzo de 2011): 658–64. http://dx.doi.org/10.1210/jc.2010-1082.
Texto completoWei, Xiaojing, Xiaodong Wang, Jie Xiong, Chen Li, Yixuan Liao, Yongjun Zhu y Jingxin Mao. "Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma". BioMed Research International 2022 (18 de mayo de 2022): 1–13. http://dx.doi.org/10.1155/2022/9959649.
Texto completoColle, Raphael, Sara Lonardi, Marine Cachanado, Michael J. Overman, Elena Elez, Marwan Fakih, Francesca Corti et al. "Impact of Lynch syndrome, BRAFV600E, and RAS mutations on outcomes in MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Analysis of combined international cohorts." Journal of Clinical Oncology 41, n.º 4_suppl (1 de febrero de 2023): 171. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.171.
Texto completoNechifor-Boilă, Adela, Ancuţa Zahan, Claudia Bănescu, Valeriu Moldovan, Doina Piciu, Septimiu Voidăzan y Angela Borda. "Impact of BRAFV600E Mutation on Event-Free Survival in Patients with Papillary Thyroid Carcinoma: A Retrospective Study in a Romanian Population". Cancers 15, n.º 16 (11 de agosto de 2023): 4053. http://dx.doi.org/10.3390/cancers15164053.
Texto completoHyman, David M., Eli Diamond, Cecile Rose Vibat, Latifa Hassaine, Jason Poole, Minal Patel, Veronica Holley et al. "Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders". Blood 124, n.º 21 (6 de diciembre de 2014): 1833. http://dx.doi.org/10.1182/blood.v124.21.1833.1833.
Texto completoVignali, Paola, Elisabetta Macerola, Anello Marcello Poma, Rebecca Sparavelli y Fulvio Basolo. "Indeterminate Thyroid Nodules: From Cytology to Molecular Testing". Diagnostics 13, n.º 18 (20 de septiembre de 2023): 3008. http://dx.doi.org/10.3390/diagnostics13183008.
Texto completoZhu, Guoquan, Yuying Deng, Liqin Pan, Wei Ouyang, Huijuan Feng, Juqing Wu, Pan Chen, Jing Wang, Yanying Chen y Jiaxin Luo. "Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy". Endocrine Connections 8, n.º 6 (junio de 2019): 754–63. http://dx.doi.org/10.1530/ec-19-0045.
Texto completoM S, Bhuvitha y Krishna G. "BRAFV600E Mutation in Papillary Carcinoma Thyroid". Annals of Pathology and Laboratory Medicine 9, n.º 6 (9 de julio de 2022): A102–108. http://dx.doi.org/10.21276/apalm.3167.
Texto completoHéritier, Sébastien, Jean-François Emile, Mohamed-Aziz Barkaoui, Caroline Thomas, Sylvie Fraitag, Sabah Boudjemaa, Florence Renaud et al. "BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy". Journal of Clinical Oncology 34, n.º 25 (1 de septiembre de 2016): 3023–30. http://dx.doi.org/10.1200/jco.2015.65.9508.
Texto completoPamedytyte, Daina, Vaida Simanaviciene, Dalia Dauksiene, Enrika Leipute, Aurelija Zvirbliene, Valdas Sarauskas, Albertas Dauksa, Rasa Verkauskiene y Birute Zilaitiene. "Association of microRNA Expression and BRAFV600E Mutation with Recurrence of Thyroid Cancer". Biomolecules 10, n.º 4 (17 de abril de 2020): 625. http://dx.doi.org/10.3390/biom10040625.
Texto completoHardee, Steven, Manju L. Prasad, Pei Hui, Catherine A. Dinauer y Raffaella A. Morotti. "Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma". Pediatric and Developmental Pathology 20, n.º 3 (8 de febrero de 2017): 206–12. http://dx.doi.org/10.1177/1093526616689628.
Texto completoGadde, Samata. "Lack of the BRAFV600E Mutation in Oral Squamous Cell Carcinoma". Journal of Medical Science And clinical Research 04, n.º 12 (25 de diciembre de 2016): 14912–16. http://dx.doi.org/10.18535/jmscr/v4i12.99.
Texto completoYoon, Jiyoung, Eunjung Lee, Ja Seung Koo, Jung Hyun Yoon, Kee-Hyun Nam, Jandee Lee, Young Suk Jo, Hee Jung Moon, Vivian Youngjean Park y Jin Young Kwak. "Artificial intelligence to predict the BRAFV600E mutation in patients with thyroid cancer". PLOS ONE 15, n.º 11 (25 de noviembre de 2020): e0242806. http://dx.doi.org/10.1371/journal.pone.0242806.
Texto completoMaaitah, Alaa Al, Moaath Alsmady, Shatha Dmour, Dana Alsmady, Ahmad Al Alwan, Mira Younis, Mohammad Al Shhab et al. "The Prevalence and Prognostic Value of BRAFV600E Mutation in Papillary Thyroid Cancer". International Journal of Human and Health Sciences (IJHHS) 3, n.º 4 (1 de septiembre de 2019): 223. http://dx.doi.org/10.31344/ijhhs.v3i4.106.
Texto completoAcosta-Medina, Aldo A., Jithma P. Abeykoon, N. Nora Bennani, Caroline Davidge-Pitts, Matthew J. Koster, Aishwarya Ravindran, Karen Rech et al. "BRAFV600E frequency and impact on outcomes in adults with langerhans cell histiocytosis." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): 7050. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.7050.
Texto completoSalem, Mohamed E., Scott Kopetz, Sherif Mohamed El-Refai, Josep Tabernero, Frank A. Sinicrope, Jeanne Tie, Thomas J. George et al. "Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E-mutated versus MSI-H BRAFwild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 3066. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3066.
Texto completoSalem, Mohamed E., Scott Kopetz, Sherif Mohamed El-Refai, Josep Tabernero, Frank A. Sinicrope, Jeanne Tie, Thomas J. George et al. "Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E-mutated versus MSI-H BRAFwild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 3066. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3066.
Texto completoBaldari, Silvia, Giuliana Di Rocco, Marie C. Heffern, Timothy A. Su, Christopher J. Chang y Gabriele Toietta. "Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells". Cancers 11, n.º 5 (12 de mayo de 2019): 659. http://dx.doi.org/10.3390/cancers11050659.
Texto completoWieczorek-Szukala, Katarzyna, Janusz Kopczynski, Aldona Kowalska y Andrzej Lewinski. "Snail-1 Overexpression Correlates with Metastatic Phenotype in BRAFV600E Positive Papillary Thyroid Carcinoma". Journal of Clinical Medicine 9, n.º 9 (21 de agosto de 2020): 2701. http://dx.doi.org/10.3390/jcm9092701.
Texto completoChoden, Sonam, Somboon Keelawat, Chan Kwon Jung y Andrey Bychkov. "VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer". Cancers 12, n.º 3 (5 de marzo de 2020): 596. http://dx.doi.org/10.3390/cancers12030596.
Texto completoLee, Hey Min, Stefania Napolitano, Van K. Morris, Kunal Rai, John Paul Y. C. Shen, Jennifer S. Davis, Dipen M. Maru et al. "Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC." Journal of Clinical Oncology 39, n.º 3_suppl (20 de enero de 2021): 110. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.110.
Texto completo